Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU Regulation Recap: IVDR Chapter II – Economic Operators, Reprocessing, CE-Marking And Free Movement

Executive Summary

In the third article of a series that takes a deep dive into the EU's forthcoming Medical Device and IVD Regulations, Medtech Insight focuses on the second chapter of the IVD regulatory text. This chapter looks at the making available and putting into services of devices, obligations of economic operators, reprocessing, CE-marking and free movement.

You may also be interested in...



EU Regulation Recap: Economic Operators, Reprocessing, CE Marking And Free Movement

A detailed look at the second of 10 chapters of the new EU Medical Devices Regulation, which is pending final adoption. The chapter focuses on the making available and putting devices into service, obligations of economic operators, reprocessing, CE marking and free movement. Part of an ongoing series.

EU Regulation Recap: A Look At Scope And Definitions In New EU Rules

The EU takes a breather over its summer months after an intense period of discussion about the future Medical Device and IVD Regulations. Taking a broad overview of the new regulatory texts, what do we know about the key changes they will bring? This piece looks at the most noteworthy elements of the MDR and IVDR scope and definitions sections. Look for recaps of other sections in the weeks ahead.

EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency

Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel